



FOR IMMEDIATE RELEASE

August 1, 2019

Contact: Jacqueline Clark, [jacqueline@sqcomms.com](mailto:jacqueline@sqcomms.com)

Charlie Patterson, [charlie@sqcomms.com](mailto:charlie@sqcomms.com)

### **Biopharmaceutical Research Company (BRC) Applauds Continued Congressional Efforts to Expand Cannabis Research**

**MONTEREY, CA** - Biopharmaceutical Research Company (BRC) praised the latest congressional effort to increase access to federally compliant, American-grown cannabis strictly for use by researchers. A bill introduced today by Senator Dick Durbin (D-IL) would transition cannabis from Schedule I to Schedule III under the Controlled Substances Act and provide research objectives to federal science and health agencies.

“With Senator Durbin’s new legislation, the Medical Marijuana Research Act in the House and other efforts to expand research all being introduced in such a short window, we are encouraged that the levee may be breaking our way and opening the door for critical research into the medicinal value and limitations of cannabis,” said George Hodgin, a former Navy SEAL and founder and CEO of BRC. “This research could yield vital insight into new treatments for veterans with post-traumatic stress, chronic pain and other ailments associated with combat.”

“As a pending Drug Enforcement Administration (DEA) registrant to supply cannabis for research, we have been waiting nearly three years to be allowed to begin growth and research operations. Though we still believe the most effective and quickest path is for the DEA to issue the licenses it promised three years ago as soon as possible, we are heartened by the efforts of our friends in Congress to promote innovation and uncover new treatments from cannabis-derived products.”

#### **About Biopharmaceutical Research Company**

BRC currently holds a DEA Registration and is working with the DEA for approval to manufacture clean, consistent and compliant cannabis for federally approved researchers around the world. BRC also conducts federally compliant cannabis-specific analytical activities.

George Hodgin is a graduate of the Stanford Graduate School of Business, a former Navy SEAL and the CEO of Biopharmaceutical Research Company near Monterey, CA. To learn more about BRC’s work, visit <https://www.biopharmaresearchco.com/>.

###